Quevedo–Florez LA, Nariño–Gonzalez D, Aguiar-Martinez LG, Salazar-Ibarra E

Language: Spanish
References: 21
Page: 99-103
PDF size: 103.37 Kb.

ABSTRACT

Introduction: The use of botulinum toxin is part of the treatment of many medical conditions, which is practiced widely given its evidence on adequate therapeutic response with acceptable clinical safety. However, iatrogenic botulism is a serious complication with few cases reported in the literature. Case report: A 65-year-old woman with a history of cervical dystonia treated with botulinum toxin every 3 months, who consults for dyspnea as the main symptom. The physical examination showed flaccid dysarthria, flaccid paralysis of the tongue, difficulty breathing progressing to ventilatory failure with subsequent need of tracheostomy and gastrostomy until the end effect of botulinum toxin. Conclusion: Iatrogenic botulism is a severe complication that may arise in relation to this treatment. This rare complication of the medical grade botulinum toxin can severely affect the quality of life of the patients.

REFERENCES

1. Jost WH, Hefter H, Stenner A, Reichel G. Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy. J Neural Transm 2013 Mar;120(3):487- 496.

2. Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord 2007 Oct;13(7):411-416.

3. Chapman MA, Barron R, Tanis DC, Gill CE, Charles PD. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 2007 Jul;29(7):1325-1337.

4. Swope D, Barbano R. Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurol Clin 2008 May;26 Suppl 1:54-65.

5. Laura Avanzino GA. How does the cerebellum contribute to the pathophysiology of dystonia?. Basal Ganglia 2012;2(4):231-235.

6. Maia FM, Kanashiro AK, Chien HF, Goncalves LR, Barbosa ER. Clinical changes of cervical dystonia pattern in long-term botulinum toxin treated patients. Parkinsonism Relat Disord 2010 Jan;16(1):8- 11.

7. Hallett M. Neurophysiology of dystonia: The role of inhibition. Neurobiol Dis 2011 May;42(2):177- 184.

8. Hutchinson M, Isa T, Molloy A, Kimmich O, Williams L, Molloy F, et al. Cervical dystonia: a disorder of the midbrain network for covert attentional orienting. Front Neurol 2014 Apr 28;5:54.

9. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008 May 6;70(19):1699-1706.

10. Shilpa PS, Kaul R, Sultana N, Bhat S. Botulinum toxin: The Midas touch. J Nat Sci Biol Med 2014 Jan;5(1):8-14.

11. Wheeler A, Smith HS. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology 2013 Apr 5;306:124-146.

12. Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 2014 Aug;12(8):535-549.

13. Sobel J. Botulism. Clin Infect Dis 2005 Oct 15;41(8):1167-1173.

14. Horowitz BZ. Botulinum toxin. Crit Care Clin 2005 Oct;21(4):825-39, viii.

15. Villar RG, Elliott SP, Davenport KM. Botulism: the many faces of botulinum toxin and its potential for bioterrorism. Infect Dis Clin North Am 2006 Jun;20(2):313-27, ix.

16. A. Goonetilleke JH. Clostridial neurotoxins. J Neurol Neurosurg Psiquiatría 2004;75(Suppl 3):35-39.

17. Dembek ZF, Smith LA, Rusnak JM. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep 2007 Nov;1(2):122-134.

18. Klein AW. Complications with the use of botulinum toxin. Dermatol Clin 2004 Apr;22(2):197-205, vii.

19. Swope D, Barbano R. Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurol Clin 2008 May;26 Suppl 1:54-65.

20. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008 May 6;70(19):1699-1706.

21. Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 2005 Jan 25;(1)(1):CD004315.